The role of the atherogenic index of plasma in response to once-daily tadalafil in men with erectile dysfunction.

IF 3 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Aging Male Pub Date : 2026-12-31 Epub Date: 2026-09-21 DOI:10.1080/13685538.2026.2737481

Cem Tuğrul Gezmiş, Nusret Can Çilesiz, Mehmet Uzut, Mustafa Satılmışoğlu, Ali Eroğlu, Buğra Çetin, Mahmut Selman Mert, Mustafa Bahadır Can Balcı

{"title":"The role of the atherogenic index of plasma in response to once-daily tadalafil in men with erectile dysfunction.","authors":"Cem Tuğrul Gezmiş, Nusret Can Çilesiz, Mehmet Uzut, Mustafa Satılmışoğlu, Ali Eroğlu, Buğra Çetin, Mahmut Selman Mert, Mustafa Bahadır Can Balcı","doi":"10.1080/13685538.2026.2737481","DOIUrl":null,"url":null,"abstract":"Background: Erectile dysfunction (ED) significantly affects quality of life, and phosphodiesterase type 5 inhibitors, including tadalafil, are main treatment options. Treatment response varies, and vasculometabolic disturbances may reduce responsiveness.Methods: In this prospective single-centre cohort study, men aged ≥40 years with ED initiating tadalafil 5 mg once daily were followed for 12 weeks. AIP was calculated as log₁₀(triglycerides/HDL-C) after conversion to mmol/L. The primary outcome was a ≥4-point increase in IIEF-EF. Firth penalised logistic regression and ROC analyses were performed.Results: Among 134 men, the response rate was 73.1%. Nonresponders had higher baseline AIP (0.196 ± 0.271 vs 0.070 ± 0.224, p = 0.008), higher BMI (28.8 ± 4.19 vs 27.4 ± 3.28 kg/m², p = 0.042), and higher prevalence of DM (30.6% vs 12.2%, p = 0.013). Each 0.1-unit AIP increase was independently associated with nonresponse (adjusted OR 1.20, 95% CI 1.01-1.44, p = 0.036), as was DM (adjusted OR 3.39, 95% CI 1.15-10.45, p = 0.027). ROC analysis yielded an AUC of 0.650 (95% CI 0.540-0.760, p = 0.008), with an optimal cutoff of 0.130.Conclusion: Higher baseline AIP was independently associated with nonresponse to once-daily tadalafil in men with ED, suggesting AIP may offer additional prognostic information, though further validation is needed.","PeriodicalId":55542,"journal":{"name":"Aging Male","volume":"29 1","pages":"2737481"},"PeriodicalIF":3.0000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aging Male","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2026.2737481","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Erectile dysfunction (ED) significantly affects quality of life, and phosphodiesterase type 5 inhibitors, including tadalafil, are main treatment options. Treatment response varies, and vasculometabolic disturbances may reduce responsiveness.

Methods: In this prospective single-centre cohort study, men aged ≥40 years with ED initiating tadalafil 5 mg once daily were followed for 12 weeks. AIP was calculated as log₁₀(triglycerides/HDL-C) after conversion to mmol/L. The primary outcome was a ≥4-point increase in IIEF-EF. Firth penalised logistic regression and ROC analyses were performed.

Results: Among 134 men, the response rate was 73.1%. Nonresponders had higher baseline AIP (0.196 ± 0.271 vs 0.070 ± 0.224, p = 0.008), higher BMI (28.8 ± 4.19 vs 27.4 ± 3.28 kg/m², p = 0.042), and higher prevalence of DM (30.6% vs 12.2%, p = 0.013). Each 0.1-unit AIP increase was independently associated with nonresponse (adjusted OR 1.20, 95% CI 1.01-1.44, p = 0.036), as was DM (adjusted OR 3.39, 95% CI 1.15-10.45, p = 0.027). ROC analysis yielded an AUC of 0.650 (95% CI 0.540-0.760, p = 0.008), with an optimal cutoff of 0.130.

Conclusion: Higher baseline AIP was independently associated with nonresponse to once-daily tadalafil in men with ED, suggesting AIP may offer additional prognostic information, though further validation is needed.

查看原文本刊更多论文

血浆动脉粥样硬化指数在勃起功能障碍男性每日一次他达拉非治疗中的作用。

背景：勃起功能障碍（ED）显著影响生活质量，磷酸二酯酶5型抑制剂，包括他达拉非，是主要的治疗选择。治疗反应各不相同，血管代谢紊乱可降低反应性。方法：在这项前瞻性单中心队列研究中，年龄≥40岁的ED患者开始服用他达拉非，每日一次，5mg，随访12周。AIP换算成mmol/L后以log₁0（甘油三酯/HDL-C）计算。主要终点为IIEF-EF升高≥4个点。进行了惩罚逻辑回归和ROC分析。结果：134例男性患者中，有效率为73.1%。无应答者基线AIP较高（0.196±0.271 vs 0.070±0.224,p = 0.008）， BMI较高（28.8±4.19 vs 27.4±3.28 kg/m²，p = 0.042）， DM患病率较高（30.6% vs 12.2%, p = 0.013）。AIP每增加0.1个单位与无反应独立相关（校正OR 1.20, 95% CI 1.01-1.44, p = 0.036）， DM也是如此（校正OR 3.39, 95% CI 1.15-10.45, p = 0.027）。ROC分析的AUC为0.650 (95% CI 0.540-0.760, p = 0.008)，最佳截止值为0.130。结论：较高的基线AIP与ED患者每日一次他达拉非无反应独立相关，表明AIP可能提供额外的预后信息，但需要进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Aging Male 医学-泌尿学与肾脏学

CiteScore

6.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： The Aging Male , the official journal of the International Society for the Study of the Aging Male, is a multidisciplinary publication covering all aspects of male health throughout the aging process. The Journal is a well-recognized and respected resource for anyone interested in keeping up to date with developments in this field. It is published quarterly in one volume per year. The Journal publishes original peer-reviewed research papers as well as review papers and other appropriate educational material that provide researchers with an integrated perspective on this new, emerging specialty. Areas of interest include, but are not limited to: Diagnosis and treatment of late-onset hypogonadism Metabolic syndrome and related conditions Treatment of erectile dysfunction and related disorders Prostate cancer and benign prostate hyperplasia.